Ultrasound and Clinicopathological Characteristics of Papillary Thyroid Carcinoma Predict the Coexistence of TERT Promoter and BRAF(V600E) Mutations

乳头状甲状腺癌的超声和临床病理特征可预测TERT启动子和BRAF(V600E)突变的共存

阅读:1

Abstract

PURPOSE: The coexistence of TERT promoter and BRAFV600E mutations is strongly linked to aggressive behavior and poor prognosis in papillary thyroid carcinoma (PTC). This study aimed to develop preoperative and postoperative predictive models for coexisting mutations based on ultrasound and clinicopathological characteristics to stratify prognostic risks and guide clinical decision-making. METHODS: Retrospective analysis of the ultrasound and clinicopathological characteristics of 120 patients with a surgical pathology of PTC with TERT promoter and BRAF(V600E) gene testing results in the Affiliated Hospital of Jining Medical University from December 2020 to December 2023. Univariate and multivariate logistic regression identified independent predictors, and nomograms were constructed. Model performance was evaluated using ROC curves, calibration curves, and decision curves, with internal validation via Bootstrap resampling. RESULTS: Age (OR: 1.24; 95% CI 1.12-1.37, P<0.001), tumor size (OR: 5.51; 95% CI 2.26-13.46, P<0.001), lateral lymph node metastasis (OR: 7.36; 95% CI 1.48-36.48, P=0.015), and irregular/ill-defined margins (OR: 6.06; 95% CI 1.19-30.75, P=0.030) were independent predictors of coexisting mutations. The cutoff values for age and tumor size were 44.5 years and 1.55 cm, respectively. Two models incorporating the four independent predictors were established to predict coexisting mutations in the preoperative and postoperative periods, achieving AUCs of 0.95 and 0.96, respectively, with both models demonstrating good calibration ability and clinical practicability through calibration and decision curve analyses. CONCLUSION: The predictive models enable clinicians to identify high-risk patients with coexisting mutations both preoperatively and postoperatively, supporting the development of individualized treatment strategies and potentially improving patient outcomes. However, the study is limited by its single-center design, and further external validation is needed to confirm the generalizability of the model.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。